Higi, which received funding from BlueCross BlueShield Venture Partners last year, has raised a further $21.3m.

The blood pump developer raised $16.3m from public investment bank BPIfrance, following a Novo Seeds-backed round two years ago.

The healthcare data analytics software provider has now raised more than $31m in total, after BlueCross BlueShield Venture Partners and Intel Capital reinvested.

Clinical data analysis platform Shyft has agreed to a $195m purchase by investor Medidata that will also allow McKesson and UnitedHealth to exit.

Merck & Co is one of the investors set to exit antibody drug developer Visterra after Otsuka Pharmaceutical agreed to buy the company for $430m.

Inra spinout Nextbiotix has attracted capital from the institute itself as well as Biocodex and other institutional investors.

EMS subsidiary Brace Pharma Capital returned to help HPV therapy developer Antiva Biosciences increase its overall funding to $57m.

Osage University Partners has returned to back a series C1 round for Antiva, which is developing treatments for HPV and is based on research at UC San Diego.

The healthtech investment firm has closed a $188m third fund featuring several care providers and insurers as limited partners.